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ABSTRACT
Objectives: Doxorubicin is one of the most important and powerful anticancer drugs, the most pronounced limitation for its use is toxicity on normal 
cells. Mechanism of doxorubicin-induced cardiotoxicity (DIC) is multifactorial and complex, including direct DNA damage, formation of free radicals, 
interference with DNA repair, and activation of immune reactions. Febuxostat is a non-purine-selective xanthine oxidase inhibitor decrease the 
production of uric acid. The aim of the present study was to evaluate the influence of febuxostat on doxorubicin-induced acute cardiotoxicity in rats 
regarding oxidative stress and antiapoptotic effects.
Methods: A total of 30 Sprague Dawley male rats were used which subdivided into three groups: Group I (negative control group) received normal 
saline for 10 days, Group II (positive control group) received normal saline plus single dose of doxorubicin (15 mg/kg, IP), and Group III (treated 
group) received febuxostat (10 mg/kg, po), for 10 successive days plus single dose of doxorubicin (15 mg/kg, I.P.). Serum brain natriuretic peptide 
(BNP), cardiac troponin I (cTn-I), caspase-3, glutathione peroxidase (GSH-Px), lipid peroxidase (LPO), malondialdehyde (MDA), and tumor necrosis 
factor alpha were estimated by ELISA kit method.
Results: Febuxostat administration before doxorubicin led to significant decrease on cardiac troponin, caspase-3, and elevation in GSH-Px levels 
significantly p<0.05. While the effects of febuxostat on BNP, LPO, MDA, tumor necrosis-alpha were insignificant p>0.05 compare to doxorubicin.
Conclusion: Febuxostat attenuates DIC through modulation of antioxidant, anti-inflammatory, and antiapoptotic biomarkers.
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INTRODUCTION
Doxorubicin is one of the most important and prominent anticancer 
drugs. Doxorubicin has the ability to fight rapid dividing cells and to 
slow the progression of the many malignant diseases [1]. However, 
clinical usefulness of doxorubicin is limited by its cumulative, dose-
dependent progressive cardiotoxicity [2].
It has been categorized three distinct types of doxorubicin-induced 
cardiotoxicity (DIC), including acute (within days), early-onset chronic 
(within weeks), and chronic progressive cardiotoxicity (within months-
years) after drug administration. Acute DIC may occur during doxorubicin 
initiation or immediately later which appears as temporary ECG 
abnormalities, while chronic DIC is presented as congestive heart failure [3].
Different molecular mechanisms are involved in DIC which is 
multifactorial and complex, include direct DNA damage, formation of 
free reactive oxygen radicals, interference with DNA repair, alterations 
of cellular calcium homeostasis, mitochondria injury, lysosomal 
changes, and apoptosis [4,5]. The heart is particularly sensitive to 
the oxidative damage due to low levels of antioxidant enzymes, large 
density of mitochondrial, and high rate of oxygen consumption [6]. 
Moreover, repeated doxorubicin administration promotes nitric oxide 
(NO) production in the myocardium through induction of inducible NO 
synthase expression. The cardiotoxic effect of NO is due to the formation 
of reactive nitrogen species which attack cellular biomolecules, causing 
energy imbalance and death [7].
Febuxostat is a non-purine-selective xanthine oxidase inhibitor, blocks 
the active site of xanthine oxidase. Hence, febuxostat decreases the 
production of uric acid [8]. Krishnamurthy et al. study demonstrated a 
significant effect of febuxostat on attenuation of DIC through reduction 
of cardiac injury biomarkers and activation of endogenous antioxidant 
capacity as febuxostat improves diastolic pressure with significant 
positive inotropic and lusitropic effects [9]. These findings give a clue 
that febuxostat could produce a cardioprotective due to its antioxidant 
effect.
Therefore, the aim of the present study was to evaluate the influence 
of febuxostat on doxorubicin-induced acute cardiotoxicity in rats 
regarding oxidative stress and antiapoptotic effects.
METHODS
A total of 30 Sprague Dawley male rats were used in this study, which 
purchased from International Center for Cancer and Medical Genetic 
Researches. Rat’s body weight ranged from 150 to 250 g with the age 
range of 3–4 month. The rats were housed in sterile cages and kept at 
25°Ċ with 12/12 light-dark cycle. The rats allowed for chow pellet and 
to drink tap water ad libitum. Humane care for animals was according 
to the conduct to the care and utilize of laboratory animal under ethical 
endorsement permission.
After 2 weeks of acclimatization period, the animals were randomly 
divided into three groups, 10 rats in each group.
• Group I: (Negative control group) Received normal saline 
(5 ml/kg/day) for 10 days.
• Group II: (Positive control group) Received normal saline 
(5 ml/kg/day) for 10 days, and on the 8th day, a single dose of 
doxorubicin (15 mg/kg, IP) (doxorubicin HCl 50 mg Pfizer USA) 
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soluble powder was given which serves as doxorubicin group.
• Group III: (Treated group) Received febuxostat (10 mg/kg, po), 
Feburic 120 mg (Alhikma co. Jordon) daily for 10 successive days, 
and on the 8th day, a 1 h after drug administration, a single dose of 
doxorubicin (15 mg/kg, I.P.) was given. The procedure of the study 
was according to Su et al. study [10].
At the 11th day of the study, rats were sacrificed and hearts were 
taken for histopathological observations, blood samples were taken 
for biochemical analysis. Blood samples were collected through 
intracardiac puncture in sterile labeled tubes, then centrifuged for 
10 min at 4500 rpm and stored at −20°C to be assessed later.
Assessment of the biochemical variables
Serum brain natriuretic peptide (BNP), cardiac troponin I (cTn-I), 
caspase-3, glutathione peroxidase (GSH-Px), lipid peroxidase (LPO), 
malondialdehyde (MDA), and tumor necrosis factor alpha (TNF-α) 
were estimated by sandwich ELISA kit method (Kono Biotech 
Company, China).
Assessment of the histopathological changes
Fixation, tissue dissection, microtome sectioning, and slide preparation 
of rat hearts were according to Ashour et al. study [11].
Statistics
Data analysis was done using IBM SPSS (IBM SPSS Statistics for Windows 
version 20.0, 2014 Armonk, NY, IBM, Corp). The data were expressed 
as mean ± standard deviation. The significance of the difference of 
different means (quantitative data) was tested using Student’s t-test 
for difference between two independent means. Statistical significance 
was considered when p<0.05.
RESULTS
Changes in the cardiac, inflammatory, oxidative, and apoptotic 
biomarkers in doxorubicin-induced acute cardiotoxicity
Results of the present study demonstrated that doxorubicin led to 
cardiotoxicity since it causes a significant elevation in the cardiac 
biomarkers. Cardiac troponin, BNP, caspase-3, and LPO were highly 
elevated compared to control p<0.01, while MDA and TNF-α were 
elevated but to a lesser extent p<0.05. In addition, GSH-Px serum 
levels were decreased significantly p<0.01 compared to control group, 
Table 1.
Febuxostat administration before doxorubicin led to a significant 
decrease in cardiac troponin, caspase-3, and elevation in GSH-Px 
levels significantly p<0.05. While the effect of febuxostat on BNP, LPO, 
MDA, tumor necrosis-alpha were insignificant P >0.05 compare to 
doxorubicin group Table 2.
Histopathological changes in doxorubicin-induced acute 
cardiotoxicity
The control group section showed normal structure of myocardial 
tissue with peripherally located normal oval nucleus and branching 
striated muscle fibers. While, the section of doxorubicin group showed 
many congested and dilated blood vessels with extravasations, edema, 
cytoplasmic vaculations, decreased number of nuclei, and loss of 
muscle fibers striation. Regarding the effect of febuxostat, it led to 
the preservation of nuclei without muscles fibers fragmentation, but 
congested and dilated blood vessels with edema and extravasations are 
seen, Fig. 1.
DISCUSSION
The present study clearly showed that doxorubicin induces myocardial 
injury by a significant elevation in plasma level of cTn-I in doxorubicin-
treated rats compared to the control. These findings are in agreement 
with the experimental research that showed the response of CTn-I to 
chemotherapy-induced acute myocardial injury [12].
It is well-known that cardiac troponin is regarded as the gold standard 
biomarker for myocardial injury and cardiotoxicity. It is only released 
into the plasma when cardiac myocytes were injured, so an increase 
in its level during treatment with doxorubicin reflects the acute 
cardiotoxicity of this chemotherapeutic agent. Thus, an elevation of 
CTn-I after a high dose of chemotherapy accurately predicts the severity 
of cardiac dysfunction [13].
Table 1: Serum level of cardiac biomarkers during 







BNP (µg/L) 10.67±1.63 17.17+1.94 0.0001*
Caspase-3 (pmol/L) 13.33±2.42 24.67±4.59 0.0003*
Cardiac troponin (ng/L) 17±3.41 42.0±7.54 0.0001*
GSH (pmol/L) 24.83±3.97 14.5±4.32 0.001*
LPO (nmol/L) 14.83±1.72 26.17±7.83 0.006*
MDA (nmol/L) 1.1±0.414 1.933±0.74 0.03
TNF (ng/L) 23.17±11.09 37.33±8.96 0.03
Results are expressed as mean±SD; *p<0.01, p<0.05, BNP: Brain 
natriuretic peptide, GSH: Glutathione peroxidase, LPO: Lipid peroxidase, 
MDA: Malondialdehyde, TNF: Tumor necrosis factor alpha
Table 2: Effects of febuxostat on cardiac biomarker levels during 






BNP (μg/L) 17.17+1.94 15.8±1.788 0.25
Caspase-3 (pmol/L) 24.67±4.59 20.4±1.14 0.03*
Cardiac troponin (ng/L) 42.0±7.54 32.8±4.21 0.03*
GSH (pmol/L) 14.5±4.32 19.2±3.34 0.02*
LPO (nmol/L) 26.17±7.83 24.6±2.23 0.40
MDA (nmol/L) 1.933±0.74 1.60±0.15 0.14
TNF (ng/L) 37.333±8.96 34.0±3.83 0.25
Results are expressed as mean±SD; *p<0.05, BNP: Brain natriuretic peptide, 
GSH: Glutathione peroxidase, LPO: Lipid peroxidase, MDA: Malondialdehyde, 
TNF: Tumor necrosis factor alpha
Fig. 1: Sections of myocardial tissue, magnification ×40 (H and E). 
(a) (Control) Section showed normal rat myocardial tissue, 
(b) (doxorubicin) section showed congested and dilated blood 
vessel fragmented muscles fibers (orange arrow), decreased 
number of nuclei due to doxorubicin-induced acute cardiotoxicity, 
(c) (febuxostat) section showed preserved nuclei and no muscles 
fibers fragmentation but congested and dilated blood vessels 
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Therefore, the results of the present study pointed out that rats which 
were pre-treated with febuxostat showed reduction in CTn-I which is 
agreed with the previous study that has been described the response of 
cardiac troponins to DIC [14].
As well, the present study showed a significant increase in LPO in 
doxorubicin group compared to control group that corresponds with 
Khan et al. study that demonstrated a significant elevation in LPO 
levels in DIC [15]. Increase in LPO level could be attributed to the 
cardiomyocyte toxic effects of free radical oxidative degradation of 
doxorubicin [16].
Moreover, the results of the present study illustrated that rats which 
pre-treated with febuxostat showed significant decrease in LPO serum 
level compared to doxorubicin-treated rats, this finding is in agree with 
Wang et al. study that showed febuxostat therapy in animal model study 
causes a significant decline in serum levels of LPO due to inhibition of 
free radical generation [17].
Furthermore, MDA levels were significantly increased in the 
doxorubicin-treated rats compared to control group. This finding 
confirms the role of free radicals in DIC. Increase in MDA level could be 
attributed to the effects of free radicals that are generated as a result of 
doxorubicin effect, on NADH-dependent microsomal LPO that initiates 
lipid radical chain and oxidative damage [18,19]. Also, pre-treatment 
with febuxostat led to significant decrease in MDA serum level 
compared to doxorubicin treated rats which coincided with a study 
that demonstrated a significant decrease in MDA serum levels during 
febuxostat treatment [20].
Furthermore, TNF was significantly increased in doxorubicin group 
compared to the control group. Interestingly, both myocardial 
macrophages and cardiac myocytes synthesize TNF-α. Accumulating 
evidence indicates that myocardial TNF-α is an autocrine contributor 
to myocardial dysfunction and cardiomyocyte death in ischemia-
reperfusion injury a sepsis and chronic heart failure [21].
Moreover, pre-treated with febuxostat showed insignificant decrease in 
serum TNF-α level compared to doxorubicin treated rats. This outcome 
is not corresponded with a study that disclosed a potential effect of 
febuxostat in reduction of pro-inflammatory cytokines [22].
In the present study, BNP was significantly increased in the doxorubicin-
treated rats compared to control group. In contrast, Ruggiero et al. 
reported low BNP serum levels during acute DIC due to inhibition of 
BNP gene expression [23]. However, in the present study, high levels of 
BNP were due to the development of acute heart failure as BNP serum 
levels are correlated with the severity of heart failure [24].
The cardioprotective effects of febuxostat might explain the reduction 
in BNP serum levels as febuxostat illustrates antioxidant and anti-
inflammatory effects as well as the reduction of serum uric acid which 
have deleterious effect on the cardiomyocyte [17].
Moreover, the present study showed that febuxostat decreases 
caspase-3 serum level compared to doxorubicin-treated rats. This 
results in agreement with the research that showed febuxostat 
reduced the apoptotic marker, namely caspase-3 compared 
to doxorubicin-treated rats due to the antiapoptotic effect of 
febuxostat [25].
Regarding the effect on the endogenous antioxidant capacity, 
doxorubicin produced significant decreases of GSH-Px in DIC compared 
to the control group due to free radicals formation that attacks the 
glutathione. Febuxostat significantly improves body endogenous 
capacity through augmentation of antioxidant enzymes. On the other 
hand, febuxostat was ineffective in reduction of MDA serum levels 
and oxidative stress which might due to small dose of febuxostat in 
neutralization the effect of free radicals [26].
In the present study, structural changes that demonstrated 
microscopically in the heart of doxorubicin group compared to 
normal control group. Doxorubicin induced cardiac cell injury which 
revealed as congested and dilated blood vessels, extravasations, edema, 
cytoplasmic vaculations, decreased number of nuclei, loss of muscle 
fibers striation and fragmentation with necrosis [27].
In rats treated with febuxostat, the cardiac cells maintained their 
integrity by the evidence of preserved nuclei, the absence of 
fragmentation of the muscle fibers. It has been reported that febuxostat 
attenuated the cardiac cell injury by its antioxidant effect. Febuxostat 
limits the infarct size of acute myocardial infarction due to its 
antioxidant, anti-inflammatory, and antiapoptotic effect [28].
CONCLUSION
Febuxostat attenuates DIC through modulation of antioxidant, anti-
inflammatory, and antiapoptotic pathways.
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